• PDF / 169,497 Bytes
• 1 Pages / 595.245 x 841.846 pts (A4) Page_size
• 100 Downloads / 156 Views

DOWNLOAD

REPORT

---

1 S

Anorexia and hypertension: 2 case reports In a retrospective study investigating the safety and efficacy of paclitaxel and ramucirumab which were administered to 16 patients with gastric cancer at a hospital in Japan between March 2018 and December 2018, two patients [ages and sexes not stated] were described, who developed anorexia or hypertension during treatment with paclitaxel and ramucirumab for gastric cancer [routes not stated]. Both the patients had gastric cancer. They started receiving ramucirumab 8 mg/kg on days 1 and 15 and paclitaxel [Nab-paclitaxel] 100 mg/m2 on days 1, 8 and 15 followed by 1 week of treatment suspension. Paclitaxel and ramucirumab were given every 4 weeks. Subsequently, one patient developed grade ≥3 anorexia and the second patient developed grade ≥3 hypertension [time to reactions onsets and outcomes not stated]. Murakami K, et al. Clinical efficacy and safety of nab-paditaxel plus ramucirumab therapy in patients with unresectable advanced or recurrent gastric cancer. [Japanese]. Gan 803520846 to Kagaku Ryoho 47: 493-495, No. 3, Mar 2020. Available from: URL: https://pubmed.ncbi.nlm.nih.gov/32381926/ [Japanese; summarised from a translation]

0114-9954/20/1834-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved

Reactions 12 Dec 2020 No. 1834